Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.

about

Melanoma: oncogenic drivers and the immune system Role of interferon in melanoma: old hopes and new perspectives.

P2860

Q26775598-14642DB1-D258-43F0-BDB6-6A0CF2233981 Q39168894-C7E680D6-DA88-4D0A-9FA6-516A80F47057

P2860

Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.

Item

http://www.wikidata.org/entity/Q38553161

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Synergy of molecular targeted ...... sis and clinical perspectives.

@en

type

Item

label

Synergy of molecular targeted ...... sis and clinical perspectives.

@en

prefLabel

Synergy of molecular targeted ...... sis and clinical perspectives.

@en

P1476

Synergy of molecular targeted ...... asis and clinical perspectives

@en

P2093

Adrian Moy

http://www.w3.org/2001/XMLSchema#string

Fabrizio Carnevale-Schianca

http://www.w3.org/2001/XMLSchema#string

Igor Vujic

http://www.w3.org/2001/XMLSchema#string

Loretta Gammaitoni

http://www.w3.org/2001/XMLSchema#string

Maria Teresa Fierro

http://www.w3.org/2001/XMLSchema#string

Pietro Quaglino

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

A landscape of driver mutations in melanoma

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Cancer regression in patients after transfer of genetically engineered lymphocytes

Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice

Beyond BRAF: where next for melanoma therapy?

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Raf kinases in cancer-roles and therapeutic opportunities

P304

1491-1500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2015.1069272

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dario Sangiolo

M AGLIETTA

Martina Sanlorenzo

P577

2015-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26206099

http://www.w3.org/2001/XMLSchema#string

Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.

about

P2860

P2860

Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698